FGF-23 as a predictor of 6-month outcome and response to therapy in acute heart failure
| Autor: | J Plonka, A Olejnik, N Wezyk-Wylegala, L Rzepiela, K Dabrowska, A Klus, E Gawrylak- Dryja, I Bil-Lula, M Gierlotka |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | European Heart Journal. Acute Cardiovascular Care. 11 |
| ISSN: | 2048-8734 2048-8726 |
| DOI: | 10.1093/ehjacc/zuac041.158 |
| Popis: | Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This work was supported by a grant from the Institute of Medical Sciences, Univeristy of Opole, Poland Background FGF-23 is a well-known marker for phosphate metabolism and independent risk marker for cardiovascular mortality. FGF-23 can stimulate pro-fibrotic factors in myocytes and finally promote cardiac fibrosis. There is also evidence that FGF-23 levels can predict the response to the therapies in acute heart failure (AHF) patients. The aim of the study was to assess whether FGF-23 level change during an episode of AHF as well as its long-term prognostic utility in population of AHF patients. Additionally, we also aimed to evaluate correlations of FGF-23 levels with the response to therapy. Methods We analysed 112 consecutive patients admitted to ICCU between June 2019 and January 2021 due to high-risk AHF. Guidelines guided therapy of heart failure was introduced. Blood samples were collected on admission, at discharge as well as at the 30-day. Patients were then followed-up for all-cause mortality and rehospitalisations due to heart failure. Results Patients (N=112; median age 68 years, 75% men, median left ventricular ejection fraction 30% [IQR 20-38%]) had median admission levels of FGF-23 = 1278 pg/ml [283-4429], Klotho protein = 670 pg/ml [501-851], NT-proBNP = 5361 ng/l [3019-13182], and GDF-15 = 4582 pg/ml [3028-9081]. FGF-23 decreased by 70% from admission to discharge (P Conclusion Levels of FGF-23 on admission in patients with AHF are significantly elevated and lowers during appropriate effective therapy what indicates the utility of FGF-23 as a typical biomarker. High values of FGF-23 are associated with higher 6-month mortality. Reduction of the FGF-23 during hospitalization can serve as a marker of AHF compensation, thus FGF-23 could be a valuable tool for assessing response to treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|